Bladder cancer that has grown into the muscle wall.

Muscle-invasive bladder cancer is urothelial cancer that has spread past the bladder lining and into the muscle beneath it. That single fact changes the goal of treatment, because it raises the risk of spread and calls for treatment of the whole body, not just the bladder.

Three short steps using the reports you already have. Nothing is uploaded and nothing leaves your device.

What it is

Cancer that begins in the bladder lining and invades the muscle layer of the bladder wall (stage T2 or higher).

Most common type

Urothelial carcinoma. Other variant types occur and can change treatment.

How it is confirmed

Tissue removed during a cystoscopy procedure (TURBT), reviewed by a pathologist, plus imaging to check for spread.

Why the muscle matters

Once cancer reaches muscle, it has better access to blood and lymph vessels, so treatment aims at the whole body as well as the bladder.

Main treatment goal

Cure, usually with chemotherapy before surgery to remove the bladder, or with a bladder-preserving combination of surgery, chemotherapy, and radiation.

What muscle invasion means

The bladder wall has layers. The inner lining is where most bladder cancers start. If cancer stays in that lining it is called non-muscle-invasive, and it is generally treated with procedures and medicine placed directly into the bladder.

Muscle-invasive disease is different. The cancer has grown into the muscular layer, which is rich in blood and lymph vessels. This raises the chance that cells have travelled elsewhere, even when scans look clear, which is why treatment usually combines a local approach with drug therapy that reaches the whole body.

• Non-muscle-invasive: confined to the lining, treated locally.
• Muscle-invasive: into the muscle, treated locally and systemically.
• Metastatic: spread to distant organs, treated systemically.

How it is diagnosed and staged

Diagnosis starts with a look inside the bladder using a camera (cystoscopy) and removal of tissue through the urethra, a procedure called TURBT. The pathologist reports whether muscle is involved, the grade, and whether any variant type is present.

Imaging of the abdomen, pelvis, and chest then looks for spread to lymph nodes or other organs. Kidney function, hearing, and general fitness are also assessed, because those results determine whether cisplatin chemotherapy is an option, which is one of the most consequential decisions in the whole pathway.

Why these findings drive treatment

Almost every treatment decision follows from a small set of results: whether muscle is invaded, whether disease has spread, and whether the person can receive cisplatin. Together these determine whether the aim is cure, whether chemotherapy comes before surgery, and whether keeping the bladder is realistic.

The Treatments section maps this out step by step, from established standard of care through to investigational approaches, and shows which test result opens each option.

Terms, in plain language

Urothelial carcinoma

The most common type of bladder cancer, starting in the cells that line the inside of the bladder.

TURBT

Transurethral resection of bladder tumour. A procedure that removes bladder tissue through the urethra, used to diagnose and stage the cancer.

Muscularis propria

The muscle layer of the bladder wall. Cancer reaching this layer is what makes disease muscle-invasive.

Radical cystectomy

Surgery to remove the bladder, together with nearby lymph nodes, and to create a new way for urine to leave the body.

Neoadjuvant

Treatment given before surgery.

Adjuvant

Treatment given after surgery to lower the risk of return.

Trimodality therapy

A bladder-preserving approach that combines tumour removal, chemotherapy, and radiation instead of removing the bladder.

Cisplatin eligibility

Whether a person can safely receive cisplatin chemotherapy, judged mainly on kidney function, hearing, nerve function, and overall fitness.

Framing follows National Comprehensive Cancer Network and American Urological Association / European Association of Urology. Last reviewed July 2026.